<DOC>
	<DOCNO>NCT00005072</DOCNO>
	<brief_summary>RATIONALE : Inserting gene interleukin-2 person 's prostate cancer cell may make body build immune response kill tumor cell . PURPOSE : Phase I/II trial study effectiveness Leuvectin treating patient locally recurrent prostate cancer receive treatment radiation therapy .</brief_summary>
	<brief_title>Leuvectin Treating Patients With Locally Recurrent Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity tolerability Leuvectin patient locally recurrent organ-confined prostate cancer radiotherapy . II . Determine efficacy regimen prevent delay manifestation disease progression demonstrate biochemical failure clinical recurrence patient population . OUTLINE : This open-label , multicenter study . Patients receive Leuvectin intraprostatically 10-30 second transrectal ultrasound guidance day 0 14 . Patients re-evaluated week 10 . Treatment repeat every 10-11 week 1-6 day completion week 10 re-evaluation maximum 3 course absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year every 6 month 2 year absence disease progression . ACTUAL ACCRUAL : A total 25 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove locally recurrent organconfined prostate cancer external beam radiotherapy , radiation seed implant , cryosurgery . Gleason score least 6 . Prostate specific antigen value ( PSA ) least 1.0 ng/mL 2 consecutive rise PSA least 2 week apart , second increase great first , achieve nadir . Must least 3 recorded PSA value minimum last 3 month determine slope . Patients must decline additional conventional treatment ineligible conventional treatment prostate cancer . No metastasis bone scan . No significant central nervous system ( CNS ) disease . PATIENT CHARACTERISTICS : Age : 18 . Performance status : Karnofsky 80100 % OR Eastern Cooperative Oncology Group ( ECOG ) 0 1 . Life expectancy : Not specify . Hematopoietic : White blood cell count ( WBC ) great 3,000/mm3 . Platelet count great 100,000/mm3 . Hemoglobin great 9.0 g/dL . Hepatic : Bilirubin normal . Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamicpyruvic transaminase ( SGPT ) less 3 time upper limit normal . Albumin great 3 g/dL . Prothrombin time ( PT ) partial thromboplastin time ( PTT ) normal . Hepatitis B surface antigen negative . Renal : Creatinine normal . Cardiovascular : No uncontrolled hypertension . No significant cardiovascular disease , e.g . : History ventricular dysfunction ; Congestive heart failure ; Symptoms coronary artery disease ; History ventricular arrhythmia ; Prior myocardial infarction . Other : HIV negative . Fertile patient must use effective doublebarrier contraception 3 month study participation . No active autoimmune disease . No active infection require IV antibiotic . No uncontrolled diabetes mellitus . No significant psychiatric disorder would preclude study . No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer . PRIOR CONCURRENT THERAPY : Biologic therapy : No prior Leuvectin . Chemotherapy : At least 3 week since prior chemotherapy ( 6 week mitomycin hydroxyurea ) . Endocrine therapy : No prior hormonal therapy prostate cancer . Radiotherapy : See Disease Characteristics . At least 3 week since prior radiotherapy . Surgery : At least 1 month since prior intrathoracic intraabdominal surgery . At least 2 week since prior major surgery . Other : At least 10 day since prior anticoagulant nonsteroidal antiinflammatory agent . No neoadjuvant concurrent anticancer drug therapy . No concurrent immunosuppressive drug . No concurrent experimental therapy .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>